Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children’s Hospital of Fudan University
During the first 12 months of expanded access treatment in China, 41 patients received naxitamab therapy with a cumulative 451 infusions administered. Over the course of this expanded access program, a reduction in the AR rate, including serious ARs, was observed as more patients were initiated and proceeded to later treatment cycles. While additional research is needed, the observed decrease in the AR rate may be attributed to clinicians' increased knowledge of AR management and hands-on experience with naxitamab-treated patients.
Authors
- K. Dong (ORCID: https://orcid.org/0009-0006-0965-5582)
- Xiaowen Qian (ORCID: https://orcid.org/0000-0002-0072-6632)
- Xiaowen Zhai (ORCID: https://orcid.org/0000-0002-3505-0302)
- James Eldridge
- Peijun Zhuang (ORCID: https://orcid.org/0000-0003-4979-7922)
- Dufei Zhang
- Kai Li (ORCID: https://orcid.org/0000-0003-0608-4105)
- Yan Li
- Weiming Chen (ORCID: https://orcid.org/0000-0003-4868-1602)
- Hongsheng Wang (ORCID: https://orcid.org/0000-0002-0054-4820)
- Zhixian Lei
Institutions
- Children's Hospital of Fudan University (CN)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1007/s40801-024-00468-5
- Citations
- 2
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- Cyrus Tang Foundation